Latest News - Psoriasis

Tuesday, October 09, 2018

Online Care May Be As Effective as In-Person Care for Psoriasis

Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic sk…

Read the full story

Monday, October 08, 2018

Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasis

The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion …

Read the full story

Friday, October 05, 2018

EPI Acquires Rights to Cloderm Cream from Promius Pharma

EPI Health has acquired the rights rights to Cloderm® (clocortolone pivalate) Cream, 0.1% and its authorized generic from Promius Pharma, LLC, a wholly owned subsidiary of D…

Read the full story

Tuesday, October 02, 2018

Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials

Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe p…

Read the full story

Monday, September 17, 2018

UCB: Study Data for Cimzia and Bimekizumab Presented at EADV

UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along wit…

Read the full story

Monday, September 17, 2018

Almirall and Evotec Form Dermatology Research Collaboration

Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debi…

Read the full story

Tuesday, September 04, 2018

AbbVie to Present New Data at 27th EADV Congress

AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12…

Read the full story

Thursday, August 30, 2018

Psoriasis Myths, Stigmas Abound

Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to multidisciplinary research from the Perelman School of M…

Read the full story

Wednesday, August 29, 2018

FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasis

The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis.…

Read the full story

Thursday, August 23, 2018

Lupin Launches Generic Clobetasol Cream in the US

Lupin has launched its Clobetasol Propionate Cream 0.05%, having received approval from the FDA earlier. Lupin's Clobetasol Propionate Cream USP 0.05% is the generic equivalent of Fougera Pharmac…

Read the full story

Tuesday, August 21, 2018

Report: Psoriasis in America in 2018

Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms -- and the mental…

Read the full story

Tuesday, August 21, 2018

MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasis

MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from…

Read the full story

Thursday, August 16, 2018

Ortho Dermatologics Resubmits NDA for Duobrii Lotion

Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; …

Read the full story

Tuesday, August 14, 2018

Burt’s Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimen

Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a s…

Read the full story

Monday, August 13, 2018

Escalier Biosciences’ Doses First PsO Patient with ESR-114; Announces Clinical Advisory Board

The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a sig…

Read the full story
Load More